Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talabostat and pemetrexed in advanced NSCLC
NCT00290017Phase 3Terminated
- Sponsor
- Point Therapeutics
- Start
- Feb 2006
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of talabostat in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Point Therapeutics. Primary endpoint: Progression-Free Survival. Started Feb 2006; status: terminated.
02
Drugs
talabostat
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00290017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00290017.